Kevin Weil, a former science executive at OpenAI, has officially announced the launch of Warp Sciences, an artificial intelligence startup aiming to automate physical laboratory processes for drug development. According to a post on his personal X account confirmed by TechCrunch on October 22, 2026, the company successfully raised $215 million at an $865 million valuation. The funding round was led by Lightspeed, with participation from IVP, Mayfield, Lux Capital, Premji Invest, and Menlo Ventures.
Automating wet chemistry experimentation
For decades, Western biotechnology companies have frequently outsourced the synthesis of thousands of molecular variants to contract research organizations in China, such as WuXi AppTec. This process requires vast amounts of manual labor and carries significant supply chain disruption risks as geopolitical tensions escalate. Warp Sciences’ core objective is to bring the entire chemical compound synthesis and testing process back onshore through autonomous robotic systems capable of operating around the clock.
The company’s training methodology relies on direct collaboration between human experts and robotic arms. Chemists wear camera-equipped glasses and gloves integrated with tactile sensors to directly handle samples in the laboratory. Motion and force data are recorded in real time to train action models for the robots, helping them learn how to grasp test tubes, mix solvents, and carry out delicate chemical reactions without dropping or breaking equipment.
The trend of bringing AI into the physical world
The biomedical sector is witnessing a major shift from theoretical predictive models toward solutions that intervene directly in the physical world. Although digital molecular models have helped screen millions of potential drug candidates in silico, the pharmaceutical industry’s biggest bottleneck remains the pace of real-world validation in wet labs.
The emergence of Warp Sciences is the next piece of the puzzle after the market witnessed OpenAI’s acquisition of Orchestra Bio to deploy autonomous software for orchestrating clinical trials. While OpenAI focuses on the software management layer, Warp Sciences directly tackles the hardware manipulation bottleneck. Much like how hardware developers are seeking to integrate AI agents at the device layer, combining computer vision and force sensors promises to transform robotic laboratories into fully automated knowledge production lines in the near future.